{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=11", "query": { "intervention": "Arm 1- Dose Expansion", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 464, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:03:33.621Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02099058", "title": "A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Telisotuzumab vedotin", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2014-01-15", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099058" }, { "nct_id": "NCT03275103", "title": "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2017-09-19", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275103" }, { "nct_id": "NCT02824575", "title": "Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Adenocarcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Rebastinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2016-07", "completion_date": "2021-12-27", "has_results": false, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02824575" }, { "nct_id": "NCT03761095", "title": "A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "Unesbulin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-03-13", "completion_date": "2024-02-05", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761095" }, { "nct_id": "NCT03223610", "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Revlimid (lenalidomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 155, "start_date": "2018-02-09", "completion_date": "2029-12-12", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223610" }, { "nct_id": "NCT05541822", "title": "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Vabametkib", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abion Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2023-01-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 4, "location_summary": "Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more", "locations": [ { "city": "Lake City", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05541822" }, { "nct_id": "NCT02675946", "title": "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "GI Cancer" ], "interventions": [ { "name": "CGX1321", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curegenix Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2016-02", "completion_date": "2023-03", "has_results": false, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 25, "location_summary": "Long Beach, California • Santa Rosa, California • Denver, Colorado + 21 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02675946" }, { "nct_id": "NCT06427941", "title": "A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Local Advanced Hepatocellular Carcinoma", "Alpha-fetoprotein (AFP)-Producing Gastric Cancer", "Extragonadal Yolk Sac Tumors", "Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BGB-B2033", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-07-23", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Zion", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06427941" }, { "nct_id": "NCT05453903", "title": "A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Bleximenib", "type": "DRUG" }, { "name": "Venetoclax (VEN)", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 196, "start_date": "2022-10-04", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453903" }, { "nct_id": "NCT03179436", "title": "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2017-07-02", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-11-15T12:03:33.621Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Hackensack, New Jersey • Nashville, Tennessee + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179436" } ] }